A settlement has been reached in a whistleblower class action lawsuit brought against Johnson & Johnson who is accused of defrauding the state of Texas by misleading doctors about its antipsychotic drug Risperdal.
Johnson & Johnson's Janssen Pharmaceuticals subsidiary will pay the settlement and the whistleblower will recieve a portion of the settlement.
Filed in 2004, the originally filed whistlebower lawsuit claimed that Johnson & Johnsonhad bribed a Texas official to get Risperdal included in a preferred medication formulary operated by the state.